ライフサイエンスコーパス: suprachoroidal

1 0.001) and 25-fold (p = 0.001) higher after suprachoroidal (2744+/-1111 ng/ml) injection when compar

2 itis, compared with 20mg subtenon injection, suprachoroidal 2mg TA demonstrated much better efficacy

3 acetonide (TACA) in porcine plasma following suprachoroidal administration, which is necessary to est

4 In addition, suprachoroidal bevacizumab tissue levels declined rapidl

5 To evaluate choroidal and suprachoroidal changes following suprachoroidal injectio

6 Suprachoroidal clearance of Gd-DTPA followed first-order

7 seline, the SCS expanded significantly after suprachoroidal CLS-TA injection (16.2 mum to 27.8 mum at

8 istributed more to the inner retina, whereas suprachoroidal delivery occurred primarily at the choroi

9 l molecules should be considered to optimize suprachoroidal delivery.

10 bility measurements or after incubation with suprachoroidal fluid by measuring the amount of (35)SO(4

11 era obtained immediately after extraction of suprachoroidal fluid for permeability measurements or af

12 id suggested that all inhibitory activity in suprachoroidal fluid fractions specific to recovering ey

13 al glycosaminoglycan synthesis compared with suprachoroidal fluid from control eyes (-54%; P < 0.01;

14 Suprachoroidal fluid isolated from recovering chick eyes

15 was associated with the objective finding of suprachoroidal fluid on OCT-EDI (P = .003), and the freq

16 correlation with the presence and amount of suprachoroidal fluid on OCT-EDI (vasculitis, 0.45 [P < .

17 The presence of suprachoroidal fluid on OCT-EDI appears to correlate wit

18 Preliminary characterization of suprachoroidal fluid suggested that all inhibitory activ

19 in leakage from choroidal blood vessels into suprachoroidal fluid using Evans blue.

20 Suprachoroidal fluid was subjected to size fractionation

21 delivery to choroid-retina was in the order: suprachoroidal > intravitreal >posterior subconjunctival

22 2 vitrectomy procedures, 39 cases of delayed suprachoroidal hemorrhage (0.8%) were identified.

23 g posterior retinal tear (n = 1) and limited suprachoroidal hemorrhage (n = 1).

24 phthisis after retinal detachment (n=4), and suprachoroidal hemorrhage (n=2).

25 elevated intraocular pressure (P = .88), or suprachoroidal hemorrhage (P = .26).

26 Risk factors for development of suprachoroidal hemorrhage during pars plana vitrectomy i

27 In eyes with suprachoroidal hemorrhage during pars plana vitrectomy,

28 he vitrectomy were identified as the delayed suprachoroidal hemorrhage group; all other eyes that und

29 nificant risk factors for developing delayed suprachoroidal hemorrhage included advancing age (odds r

30 Suprachoroidal hemorrhage is an uncommon but serious com

31 The prognosis is more favorable if the suprachoroidal hemorrhage is localized and does not exte

32 In most cases, intraoperative drainage of suprachoroidal hemorrhage is not associated with a bette

33 Delayed suprachoroidal hemorrhage occurs in 0.8% of vitrectomize

34 Suprachoroidal hemorrhage was more common with increasin

35 owed that the stronger predictors of delayed suprachoroidal hemorrhage were emesis postoperatively (P

36 All eyes that developed delayed suprachoroidal hemorrhage within 48 hours of the end of

37 stoperative adverse events (endophthalmitis, suprachoroidal hemorrhage, retinal detachment) following

38 itis, endophthalmitis, hypotony maculopathy, suprachoroidal hemorrhage, retinal detachment, stromal n

39 trectomy in the same period, without delayed suprachoroidal hemorrhage, were considered the control g

40 t anterior chamber, choroidal effusions, and suprachoroidal hemorrhage.

41 i, focal depigmentation, and the presence of suprachoroidal hyporeflective space.

42 howed much less vitreous inflammation in the suprachoroidal injection group (p<0.0001).

43 Suprachoroidal injection is an emerging technique for dr

44 Suprachoroidal injection of CLS-TA does not alter choroi

45 sion (TANZANITE) study who received either a suprachoroidal injection of CLS-TA with an intravitreal

46 he current study was designed to compare the suprachoroidal injection of different drug formulations

47 It seems that a 50muL suprachoroidal injection of TA was well tolerated in rab

48 oroidal and suprachoroidal changes following suprachoroidal injection of triamcinolone acetonide inje

49 dema due to RVO, enrolled in the prospective Suprachoroidal Injection of Triamcinolone Acetonide with

50 sure (AUC(0-360min)) to choroid-retina after suprachoroidal injection was 6-fold (p = 0.001) and 2-fo

51 umab or a viscoelastic-enhanced microcannula suprachoroidal injection was performed with either 1.25

52 After 50muL TA (Kenalog-40) suprachoroidal injection, 4-5 animals at 7 time points w

53 Suprachoroidal injection, a new approach for drug delive

54 After suprachoroidal injection, IOP had an acute elevation, hi

55 Following a 50muL suprachoroidal injection, peak TA concentration in the a

56 ficantly smaller IOP elevation than after TA suprachoroidal injection.

57 ) was observed immediately after dosing with suprachoroidal injections and at 10 and 27.5 minutes, re

58 Suprachoroidal injections are feasible in a rat model.

59 Suprachoroidal injections of fluorescein and fluorescent

60 Suprachoroidal injections resulted in the highest bioava

61 te factors responsible for visibility of the suprachoroidal layer (SCL) and suprachoroidal space (SCS

62 s a hyporeflective band corresponding to the suprachoroidal layer (SCL).

63 ontrast, intrascleral infusions expanded the suprachoroidal layer and delivered Gd-DTPA to the poster

64 but fetal eyes, SM cells were present in the suprachoroidal layer, forming a reticulum of flattened l

65 In a rabbit model, suprachoroidal polypropylene and gold shunts allow acces

66 aF was compared in Sprague Dawley rats after suprachoroidal, posterior subconjunctival, or intravitre

67 g administration by various routes including suprachoroidal route.

68 rapy showed a trend toward thickening of the suprachoroidal space (SCS) compared with monotherapy alo

69 bility of the suprachoroidal layer (SCL) and suprachoroidal space (SCS).

70 om 20 nm to 10 mum remained primarily in the suprachoroidal space and choroid for a period of months

71 Infusion cannulas were placed into the suprachoroidal space and fluid-air exchange (FAE) was st

72 r positioning of the infusion cannula in the suprachoroidal space and may lead to sudden compromise o

73 The suprachoroidal space appears to be an expandible conduit

74 ollections of fluid in the outer choroid and suprachoroidal space as seen in other forms of choroidal

75 s indicated localization of India ink to the suprachoroidal space below sclera, following injection.

76 rom an infusion cannula malpositioned in the suprachoroidal space can transit through the eye to the

77 Half-lives in the suprachoroidal space for molecules of molecular weight f

78 ing PPV to show that air can travel from the suprachoroidal space into the central circulation.

79 ell line C918 were implanted in the superior suprachoroidal space of 11 WAG/Nij-rnu nude rats.

80 -1 spheroids were grown and implanted in the suprachoroidal space of 20, 17, and 16 WAG/RijHs-rnu nud

81 oma spheroids were implanted in the superior suprachoroidal space of 26 WAG/RijHsd-rnu nude rats.

82 of molecules and particles injected into the suprachoroidal space of the rabbit eye in vivo using a h

83 ts placed in the deep sclera adjacent to the suprachoroidal space resulted in high levels of CsA in m

84 demonstrated expansion of the tissues in the suprachoroidal space that normalized after infusion term

85 thin the ciliary muscle and then through the suprachoroidal space to the posterior pole of the eye.

86 Injection into the suprachoroidal space using a microneedle offers a simple

87 scleral lamellar CsA implant adjacent to the suprachoroidal space was effective in achieving therapeu

88 No adverse effects of injection into the suprachoroidal space were observed.

89 By targeting the suprachoroidal space, the concentration of injected mate

90 on of ICG solution than TA suspension in the suprachoroidal space.

91 circumferentially around the eye within the suprachoroidal space.

92 le than does a similar dose delivered to the suprachoroidal space.

93 For comparative efficacy study, 50muL (2mg) suprachoroidal TA versus 20mg subtenon TA were performed